No, won't do that this year but EBITDA will remain consistent around $135-150M witha view of $200-220M in 2021 thats not even factoring in generic drug pricing upswings.
Book value is 80c and if a take over will eventuate won't occur sub 75c. Sentiment around generic pricing is the elephant in the room.
This is an economy of scale issue and whether generic drug pricing will rebound. No different to gold stocks when POG is in the doldrums except a viable price index on generic drugs is almost non existent. Not expecting much until late in the year... October/November is when trading updates are released for HY results and one does expect generic drug pricing to rebound by then.
MYX Price at posting:
50.5¢ Sentiment: None Disclosure: Held
